We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
Read MoreHide Full Article
Did you analyze how Exelixis (EXEL - Free Report) fared in its international operations for the quarter ending September 2026? Given the widespread global presence of this drug developer, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.
In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must understand a company's dependence on overseas markets, as this offers a window into the company's earnings stability, its ability to benefit from varied economic cycles and its potential for long-term growth.
Being present in foreign markets serves as protection against local economic declines and helps benefit from more rapidly expanding economies. Yet, such expansion also introduces challenges related to currency fluctuations, geopolitical uncertainties and varied market behaviors.
Our review of EXEL's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts.
The company's total revenue for the quarter stood at $658.7 million, increasing 10.2% year over year. Now, let's delve into EXEL's international revenue breakdown to gain insights into the significance of its operations beyond home turf.
Trends in EXEL's Revenue from International Markets
Japan generated $5.3 million in revenues for the company in the last quarter, constituting 0.8% of the total. This represented a surprise of -34.58% compared to the $8.1 million projected by Wall Street analysts. Comparatively, in the previous quarter, Japan accounted for $4.32 million (0.7%), and in the year-ago quarter, it contributed $6.33 million (1.1%) to the total revenue.
During the quarter, Europe contributed $44.3 million in revenue, making up 6.7% of the total revenue. When compared to the consensus estimate of $44.9 million, this meant a surprise of -1.34%. Looking back, Europe contributed $46.01 million, or 7.3%, in the previous quarter, and $44.97 million, or 7.5%, in the same quarter of the previous year.
Revenue Projections for Overseas Markets
The current fiscal quarter's total revenue for Exelixis, as projected by Wall Street analysts, is expected to reach $673.39 million, reflecting an increase of 12.5% from the same quarter last year. The breakdown of this revenue by foreign region is as follows: Japan is anticipated to contribute 1.3% or $8.69 million, and Europe 6.7% or $45.41 million.
For the entire year, the company's total revenue is forecasted to be $2.55 billion, which is an improvement of 10% from the previous year. The revenue contributions from different regions are expected as follows: Japan will contribute 1.3% ($33.81 million), and Europe 6.9% ($175.88 million) to the total revenue.
Closing Remarks
The dependency of Exelixis on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.
In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.
We at Zacks strongly focus on the dynamic earnings forecast of companies, given that empirical studies have demonstrated its potent impact on the immediate price movement of stocks. Invariably, there's a positive relationship -- upward earnings predictions often result in an increase in stock prices.
With an impressive externally audited track record, our proprietary stock rating tool - the Zacks Rank - harnesses the power of earnings estimate revisions and serves as an effective indicator of a stock's near-term price performance.
A Look at Exelixis' Recent Stock Price Performance
The stock has witnessed an increase of 18.8% over the past month versus the Zacks S&P 500 composite's a decrease of 0.9%. In the same interval, the Zacks Medical sector, to which Exelixis belongs, has registered an increase of 8.2%. Over the past three months, the company's shares saw an increase of 28.3%, while the S&P 500 increased by 2.2%. In comparison, the sector experienced an increase of 8.2% during this timeframe.
View the Zacks #1 Rank List
Image: Bigstock
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations
Did you analyze how Exelixis (EXEL - Free Report) fared in its international operations for the quarter ending September 2026? Given the widespread global presence of this drug developer, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.
In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must understand a company's dependence on overseas markets, as this offers a window into the company's earnings stability, its ability to benefit from varied economic cycles and its potential for long-term growth.
Being present in foreign markets serves as protection against local economic declines and helps benefit from more rapidly expanding economies. Yet, such expansion also introduces challenges related to currency fluctuations, geopolitical uncertainties and varied market behaviors.
Our review of EXEL's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts.
The company's total revenue for the quarter stood at $658.7 million, increasing 10.2% year over year. Now, let's delve into EXEL's international revenue breakdown to gain insights into the significance of its operations beyond home turf.
Trends in EXEL's Revenue from International Markets
Japan generated $5.3 million in revenues for the company in the last quarter, constituting 0.8% of the total. This represented a surprise of -34.58% compared to the $8.1 million projected by Wall Street analysts. Comparatively, in the previous quarter, Japan accounted for $4.32 million (0.7%), and in the year-ago quarter, it contributed $6.33 million (1.1%) to the total revenue.
During the quarter, Europe contributed $44.3 million in revenue, making up 6.7% of the total revenue. When compared to the consensus estimate of $44.9 million, this meant a surprise of -1.34%. Looking back, Europe contributed $46.01 million, or 7.3%, in the previous quarter, and $44.97 million, or 7.5%, in the same quarter of the previous year.
Revenue Projections for Overseas Markets
The current fiscal quarter's total revenue for Exelixis, as projected by Wall Street analysts, is expected to reach $673.39 million, reflecting an increase of 12.5% from the same quarter last year. The breakdown of this revenue by foreign region is as follows: Japan is anticipated to contribute 1.3% or $8.69 million, and Europe 6.7% or $45.41 million.For the entire year, the company's total revenue is forecasted to be $2.55 billion, which is an improvement of 10% from the previous year. The revenue contributions from different regions are expected as follows: Japan will contribute 1.3% ($33.81 million), and Europe 6.9% ($175.88 million) to the total revenue.
Closing Remarks
The dependency of Exelixis on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.
In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.
We at Zacks strongly focus on the dynamic earnings forecast of companies, given that empirical studies have demonstrated its potent impact on the immediate price movement of stocks. Invariably, there's a positive relationship -- upward earnings predictions often result in an increase in stock prices.
With an impressive externally audited track record, our proprietary stock rating tool - the Zacks Rank - harnesses the power of earnings estimate revisions and serves as an effective indicator of a stock's near-term price performance.
Exelixis, bearing a Zacks Rank #4 (Sell), is expected to underperform the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
A Look at Exelixis' Recent Stock Price Performance
The stock has witnessed an increase of 18.8% over the past month versus the Zacks S&P 500 composite's a decrease of 0.9%. In the same interval, the Zacks Medical sector, to which Exelixis belongs, has registered an increase of 8.2%. Over the past three months, the company's shares saw an increase of 28.3%, while the S&P 500 increased by 2.2%. In comparison, the sector experienced an increase of 8.2% during this timeframe.